S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:ACRS - Aclaris Therapeutics Stock Price, Forecast & News

$1.88
+0.15 (+8.67 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$1.70
Now: $1.88
$1.91
50-Day Range
$1.56
MA: $1.74
$1.95
52-Week Range
$0.74
Now: $1.88
$8.19
Volume367,962 shs
Average Volume980,889 shs
Market Capitalization$77.81 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.09 million
Book Value$5.26 per share

Profitability

Net Income$-132,740,000.00
Net Margins-1,165.39%

Miscellaneous

Employees169
Market Cap$77.81 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.


Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics Inc (NASDAQ:ACRS) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.80. The biotechnology company earned $0.98 million during the quarter, compared to analyst estimates of $5.87 million. Aclaris Therapeutics had a negative net margin of 1,165.39% and a negative return on equity of 83.22%. View Aclaris Therapeutics' Earnings History.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aclaris Therapeutics.

What price target have analysts set for ACRS?

5 Wall Street analysts have issued 1 year target prices for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $13.00. On average, they expect Aclaris Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 378.7% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

What is the consensus analysts' recommendation for Aclaris Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

Has Aclaris Therapeutics been receiving favorable news coverage?

News stories about ACRS stock have trended neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Aclaris Therapeutics.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 6,030,000 shares, an increase of 41.5% from the October 31st total of 4,260,000 shares. Based on an average trading volume of 1,940,000 shares, the short-interest ratio is currently 3.1 days. Approximately 18.8% of the shares of the stock are sold short. View Aclaris Therapeutics' Current Options Chain.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the folowing people:
  • Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)
  • Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Frank Ruffo, Co-Founder & CFO (Age 53)
  • Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60)

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Man Group plc (9.02%), Endurant Capital Management LP (4.28%), State Street Corp (1.80%), Millennium Management LLC (0.63%), Virtu Financial LLC (0.13%) and Creative Planning (0.07%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

Which institutional investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Aclaris Therapeutics.

Which institutional investors are buying Aclaris Therapeutics stock?

ACRS stock was purchased by a variety of institutional investors in the last quarter, including Man Group plc, Endurant Capital Management LP, State Street Corp, Millennium Management LLC and Creative Planning. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $1.88.

How big of a company is Aclaris Therapeutics?

Aclaris Therapeutics has a market capitalization of $77.81 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]


MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  266 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel